Status:
COMPLETED
Special Investigation For Patients With Renal And/Or Hepatic Disorders On Aromasin
Lead Sponsor:
Pfizer
Conditions:
Breast Neoplasms
Eligibility:
All Genders
Brief Summary
The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in thi...
Detailed Description
All the patients whom an investigator prescribes the first Exemestane (Aromasin) should be registered.
Eligibility Criteria
Inclusion
- Subjects with postmenopausal breast cancer (including ovariectomy etc.).
Exclusion
- Patients cannot be evaluated.For example, not administered Exemestane (Aromasin).
Key Trial Info
Start Date :
December 1 2004
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 1 2008
Estimated Enrollment :
451 Patients enrolled
Trial Details
Trial ID
NCT00932165
Start Date
December 1 2004
End Date
November 1 2008
Last Update
July 20 2010
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.